Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Chien

Showing results (541-550 of 550) with videos related to

Pageof 55
Sort By:
You have reached the last page of results.This site can display upto 550 results.
Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
British Journal of Haematology|August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndromeKelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Leukemia|August 14, 2025
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclaxJennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Leukemia|March 6, 2026
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasmsKelly S Chien, Ziyi Li, Luca Lanino, et al.
Nature Communications|April 11, 2025
Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Bijender Kumar, et al.
Blood Cancer Discovery|January 26, 2026
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, et al.
Pageof 55

Showing results (541-550 of 550) with videos related to

Sort By:
Pageof 55
You have reached the last page of results.This site can display upto 550 results.
Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.
American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
British Journal of Haematology|August 2, 2021
Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndromeKelly S Chien, Kunhwa Kim, Graciela M Nogueras-Gonzalez, et al.
Leukemia|August 14, 2025
Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclaxJennifer Croden, Wei-Ying Jen, Jennifer Marvin-Peek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Leukemia|March 6, 2026
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasmsKelly S Chien, Ziyi Li, Luca Lanino, et al.
Nature Communications|April 11, 2025
Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Bijender Kumar, et al.
Blood Cancer Discovery|January 26, 2026
Incorporation of genomic determinants improves diagnostic accuracy of oligomonocytic chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Chong Wu, Juan Jose Rodriguez-Sevilla, et al.
Pageof 55